The pharmacokinetic, pharmacodynamic, and toxicity properties of 6-gingerol were evaluated, with a focus on its drug-likeness and ADMET profile. 6-gingerol with molecular weight of 294.18 g/mol, shows promising drug-like characteristics, meeting both Lipinski's Rule of Five and Veber's Rule. 6-gingerol has moderate lipophilicity, reflected by its logP value of 2.812, and a total polar surface area (TPSA) of 66.76 Å². Despite these favorable attributes, it exhibits low human intestinal absorption (<30%). Interestingly, it acts as a P-glycoprotein inhibitor, which may influence its ability to cross cellular membranes. Its low Caco-2 permeability (-4.589) further supports its limited absorption profile. In terms of distribution, 6-gingerol shows a moderate volume of distribution (1.64 L/kg) and binds well to plasma proteins (<90%). Importantly, it can cross the blood-brain barrier (BBB), suggesting potential central nervous system activity. Metabolic studies reveal that 6-gingerol inhibits both CYP3A4 and CYP2D6, suggesting a potential for drug interactions and altered metabolism of co-administered antifungal agents. For excretion, it demonstrates a moderate clearance rate of 14.027 mL/min/kg, supporting effective elimination from the body.